Loading
companiesCompany
Samsung Bioepis
Samsung Bioepis develops biosimilars of trastuzumab, bevacizumab and other antibodies, made by its parent Samsung Biologics at Songdo.
Overview
Samsung Bioepis was founded in 2012 as a joint venture between Samsung Biologics and Biogen and became wholly owned by Samsung Biologics in 2022. It develops biosimilars, among them trastuzumab (Ontruzant) and bevacizumab (Aybintio), which are manufactured at Samsung Biologics' Songdo plants and sold with partners in Europe and the United States.
Headquarters
Incheon, KR
Scorecard
All companies#79of 1244 companies, score 58
- approved products +12
- targets +4
- modalities +2
- regions +8
- 24-month regulatory events +2
- registry trials +30
2 approved, 0 in phase 3, 0 earlier, 2 targets, 3,623 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
Founded
2012
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)
The first targeted antibody for a solid tumour (1998), which turned HER2-positive breast cancer from the worst subtype into one of the most treatable.
ApprovedMonoclonal antibody (anti-VEGF)
Bevacizumab · Avastin (and biosimilars)
Bevacizumab is a humanised antibody that soaks up VEGF-A, the signal tumours use to grow new blood vessels. Approved in 2004, it partners chemotherapy in colorectal, ovarian, cervical, lung, kidney and liver cancer and glioblastoma, and adds to trifluridine/tipiracil in late-line bowel cancer; hypertension, protein in the urine and bleeding are its characteristic side effects.
Similar pages
- CompanySartorius
Shares Antibody manufacturing (CHO bioprocessing) and the tag manufacturing-wave.
- TechnologyDownstream purification (Protein A capture, viral clearance, polishing)
Shares Antibody manufacturing (CHO bioprocessing), Biosimilar manufacturing and comparability, Trastuzumab, Bevacizumab and the tag manufacturing-wave.
- TechnologyGMP, inspections, Form 483s and warning letters
Shares Antibody manufacturing (CHO bioprocessing), Biosimilar manufacturing and comparability and the tag manufacturing-wave.
- TechnologySingle-use bioprocessing systems
Shares Antibody manufacturing (CHO bioprocessing) and the tag manufacturing-wave.
- TechnologyThe ADC supply chain (antibody, payload-linker, conjugation, fill)
Shares Antibody manufacturing (CHO bioprocessing) and the tag manufacturing-wave.
- CompanyBiocon
Shares Biosimilar manufacturing and comparability, Trastuzumab, Bevacizumab.
- TrialTL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Shares Trastuzumab, Colorectal cancer.
- PersonHelena Earl
Shares Trastuzumab, HER2-positive breast cancer.
cancers
technologies
drugs
ApprovedMonoclonal antibody (anti-VEGF)
Bevacizumab · Avastin (and biosimilars)
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)